CPRIT awards $3 million to Emtora Biosciences, formerly called Rapamycin Holdings.

Cancer Prevention Research Institute of Texas (CPRIT) announced funding Aug. 22nd for various UT Health SA researchers and affiliates.

“CPRIT also awarded $3 million to Emtora Biosciences, formerly called Rapamycin Holdings. The award is for a clinical trial investigating a formulation of rapamycin called eRapa to treat familial adenomatous polyposis. This is an inherited disorder in which noncancerous polyps form in the digestive system early in life. If not removed, the polyps can become malignant.

Rapamycin continues to be studied globally for various medicinal uses. The UT Health San Antonio team led by Randy Strong, Ph.D., and Dave Sharp, Ph.D., is a key player in the rapamycin ecosystem.”

“eRapa™ was originally developed for use in aging studies by Dr. Z. David Sharp and Dr. Randy Strong at the Barshop Institute for Longevity and Aging Studies at UT Health San Antonio in 2009 (read more).”

Article Categories: News